Featured Research

from universities, journals, and other organizations

Less radical procedures offer similar cancer control compared to surgery for kidney cancer patients

Date:
August 12, 2014
Source:
Mayo Clinic
Summary:
Needle-guided tumor destruction procedures offer near equivalent lengths of local cancer control compared to surgery for patients with small kidney cancer tumors, according to researchers. “If validated, these data suggest that an update to clinical guidelines would be warranted,” says the study’s lead author.

Needle-guided tumor destruction procedures offer near equivalent lengths of local cancer control compared to surgery for patients with small kidney cancer tumors, according to the results of a large study published in the journal European Urology. "If validated, these data suggest that an update to clinical guidelines would be warranted," says the study's lead author, R. Houston Thompson, M.D., a Mayo Clinic urologist.

Related Articles


Dr. Thompson says radical nephrectomy -- surgical removal of the entire kidney -- has historically been the standard of care for management of kidney cancer; however, partial nephrectomy -- surgical removal of tumors from a kidney while sparing healthy tissue -has become increasingly more common because of its nephron-sparing benefits and similar cancer control. The nephron is the part of the kidney that filters out toxins from the blood.

"We undertook this study because direct comparisons of outcomes among patients with kidney cancer who have received partial nephrectomy (PN), radiofrequency ablation (RFA) -- tumor destruction using intense heat and cryoablation -- tumor destruction using extreme cold -- are lacking, especially from institutions that routinely perform all three of these procedures," Dr. Thompson says.

Researchers studied a total of 1,803 patients. Among patients with tumors 4 cm or less, 1,057 patients received PN, 180 received RFA and 187 received cryoablation. Recurrence-free survival was similar among the three treatment groups, while metastases-free survival was significantly better for patients who received PN and cryoablation when compared with patients who received RFA. For the 379 patients with 4-7 cm tumors, lengths of recurrence-free and metastases-free survival were similar between PN and cryoablation. In that group, 326 underwent PN and 53 received cryoablation.

"Cryoablation and RFA have traditionally been thought to provide inferior outcomes compared with surgical removal. Our results of near equivalent success, if correct, should encourage further investigation of these treatment modalities among patients with early stage kidney cancer," Dr. Thompson says.


Story Source:

The above story is based on materials provided by Mayo Clinic. Note: Materials may be edited for content and length.


Journal Reference:

  1. R. Houston Thompson, Tom Atwell, Grant Schmit, Christine M. Lohse, A. Nicholas Kurup, Adam Weisbrod, Sarah P. Psutka, Suzanne B. Stewart, Matthew R. Callstrom, John C. Cheville, Stephen A. Boorjian, Bradley C. Leibovich. Comparison of Partial Nephrectomy and Percutaneous Ablation for cT1 Renal Masses. European Urology, 2014; DOI: 10.1016/j.eururo.2014.07.021

Cite This Page:

Mayo Clinic. "Less radical procedures offer similar cancer control compared to surgery for kidney cancer patients." ScienceDaily. ScienceDaily, 12 August 2014. <www.sciencedaily.com/releases/2014/08/140812163318.htm>.
Mayo Clinic. (2014, August 12). Less radical procedures offer similar cancer control compared to surgery for kidney cancer patients. ScienceDaily. Retrieved October 24, 2014 from www.sciencedaily.com/releases/2014/08/140812163318.htm
Mayo Clinic. "Less radical procedures offer similar cancer control compared to surgery for kidney cancer patients." ScienceDaily. www.sciencedaily.com/releases/2014/08/140812163318.htm (accessed October 24, 2014).

Share This



More Health & Medicine News

Friday, October 24, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

IKEA Desk Converts From Standing to Sitting With One Button

IKEA Desk Converts From Standing to Sitting With One Button

Buzz60 (Oct. 24, 2014) IKEA is out with a new convertible desk that can convert from a sitting desk to a standing one with just the push of a button. Jen Markham explains. Video provided by Buzz60
Powered by NewsLook.com
Ebola Protective Suits Being Made in China

Ebola Protective Suits Being Made in China

AFP (Oct. 24, 2014) A factory in China is busy making Ebola protective suits for healthcare workers and others fighting the spread of the virus. Duration: 00:38 Video provided by AFP
Powered by NewsLook.com
WHO: Millions of Ebola Vaccine Doses by 2015

WHO: Millions of Ebola Vaccine Doses by 2015

AP (Oct. 24, 2014) The World Health Organization said on Friday that millions of doses of two experimental Ebola vaccines could be ready for use in 2015 and five more experimental vaccines would start being tested in March. (Oct. 24) Video provided by AP
Powered by NewsLook.com
Doctor in NYC Quarantined With Ebola

Doctor in NYC Quarantined With Ebola

AP (Oct. 24, 2014) An emergency room doctor who recently returned to the city after treating Ebola patients in West Africa has tested positive for the virus. He's quarantined in a hospital. (Oct. 24) Video provided by AP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:

Strange & Offbeat Stories


Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins